Trayectoria del Síndrome de Rett
Figure 2. Time course graph of Rett syndrome, illustrating the progression through the four clinical stages with temporal markers and predominant alterations in each stage, such as loss of voluntary motor skills in Stage II, stabilization of symptoms in Stage III, and progression of muscle stiffness and atrophy in Stage IV.
19955111 {19955111:436UEE9K} 1 vancouver 50 default 4527 https://neuropediatoolkit.org/wp-content/plugins/zotpress/
statussuccessupdateneededfalseinstancefalsemetarequest_last0request_next0used_cachetruedatakey436UEE9Klibraryid19955111metacreatorSummaryKyleetal.parsedDate2018numChildren1bibltdivclassquotcsl-bib-bodyquotstylequotline-height1.35quotgtnltdivclassquotcsl-entryquotstylequotclearleftquotgtnltdivclassquotcsl-left-marginquotstylequotfloatleftpadding-right0.5emtext-alignrightwidth1emquotgt1.ltdivgtltdivclassquotcsl-right-inlinequotstylequotmargin0.4em01.5emquotgtKyleSMVashiNJusticeMJ.Rettsyndromeaneurologicaldisorderwithmetaboliccomponents.OpenBiolInternet.2018cited2023Feb1982170216.Availablefromltaclass039zp-ItemURL039href039httpsroyalsocietypublishing.orgdoi10.1098rsob.170216039gthttpsroyalsocietypublishing.orgdoi10.1098rsob.170216ltagtltdivgtnltdivgtnltdivgtdataitemTypejournalArticletitleRettsyndromeaneurologicaldisorderwithmetaboliccomponentscreatorscreatorTypeauthorfirstNameStephanieM.lastNameKylecreatorTypeauthorfirstNameNeetilastNameVashicreatorTypeauthorfirstNameMonicaJ.lastNameJusticeabstractNoteRettsyndromeRTTisaneurologicaldisordercausedbymutationsintheX-linkedgenemethyl-CpG-bindingprotein2nMECP2naubiquitouslyexpressedtranscriptionalregulator.DespiteremarkablescientificprogresssinceitsdiscoverythemechanismbywhichnMECP2nmutationscauseRTTsymptomsislargelyunknown.Consequentlytreatmentoptionsforpatientsarecurrentlylimitedandcentredonsymptomrelief.ThoughttobeanentirelyneurologicaldisorderRTTresearchhasfocusedontheroleofnMECP2ninthecentralnervoussystem.HoweverthevarietyofphenotypesidentifiedinnMecp2nmutantmousemodelsandRTTpatientsimplicateimportantrolesforMeCP2inperipheralsystems.HerewereviewthehistoryofRTThighlightingbreakthroughsinthefieldthathaveledustopresentday.WeexplorethecurrentevidencesupportingmetabolicdysfunctionasacomponentofRTTpresentingrecentstudiesthathaverevealedperturbedlipidmetabolisminthebrainandperipheraltissuesofmousemodelsandpatients.SuchfindingsmayhaveanimpactonthequalityoflifeofRTTpatientsasbothdietaryanddruginterventioncanalterlipidmetabolism.UltimatelyweconcludethatathoroughknowledgeofMeCP2039svariedfunctionaltargetsinthebrainandbodywillberequiredtotreatthiscomplexsyndrome.date022018sectionpartNumberpartTitleDOI10.1098rsob.170216citationKeyurlhttpsroyalsocietypublishing.orgdoi10.1098rsob.170216PMIDPMCIDISSN2046-2441languageencollectionsAV4DY38YdateModified2026-07-15T224044Z
1.
Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol [Internet]. 2018 [cited 2023 Feb 19];8(2):170216. Available from: https://royalsocietypublishing.org/doi/10.1098/rsob.170216

Rett syndrome, a neurodevelopmental disorder linked to the X chromosome (MECP2 gene), typically progresses through four defined clinical stages that mark its developmental trajectory:

  • Stage I (Early Onset – 6 to 18 months): Subtle slowing of development, loss of interest in play, and slowing of head growth.
  • Stage II (Rapid Destruction – 1 to 4 years): Rapid regression of language and voluntary use of the hands, appearance of characteristic manual stereotypies (hand washing), irritability and breathing disorders while awake.
  • Stage III (Pseudostationary – 2 to 10 years): Stabilization of motor symptoms. It highlights apraxia, epileptic seizures and progressive scoliosis, although eye contact (eye communication) improves.
  • Stage IV (Late Motor Impairment – ​​older than 10 years): Loss of mobility or ambulation if present, rigidity, spasticity, muscle atrophy and generalized weakness. Cognitive and ocular communication functions are usually preserved in this stage.